QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-reiterates-outperform-on-achieve-life-sciences-maintains-11-price-target

Oppenheimer analyst Francois Brisebois reiterates Achieve Life Sciences (NASDAQ:ACHV) with a Outperform and maintains $11 pr...

 achieve-life-sciences-q2-2024-gaap-eps-025-misses-023-estimate

Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate ...

 oppenheimer-maintains-outperform-on-achieve-life-sciences-lowers-price-target-to-11

Oppenheimer analyst Francois Brisebois maintains Achieve Life Sciences (NASDAQ:ACHV) with a Outperform and lowers the price ...

 achieve-life-sciences-q1-2024-gaap-eps-026-misses-024-estimate

Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate ...

 achieve-life-sciences-announces-publication-of-cytisinicline-vaping-cessation-trial-results-in-jama-internal-medicine-phase-2-orca-v1-trial-showed-treatment-with-cytisinicline-more-than-doubled-odds-of-quitting-e-cigarettes-compared-with-placebo

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo...

 achieve-life-sciences-files-prospectus-related-to-offer--sale-from-time-to-time-of-up-to-131m-shares-of-common-stock-by-selling-stockholders

- SEC Filing

 jonestrading-initiates-coverage-on-achieve-life-sciences-with-buy-rating-announces-price-target-of-20

JonesTrading analyst Justin Walsh initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating and announces ...

 oppenheimer-reiterates-outperform-on-achieve-life-sciences-maintains-18-price-target

Oppenheimer analyst Francois Brisebois reiterates Achieve Life Sciences (NASDAQ:ACHV) with a Outperform and maintains $18 pr...

 achieve-life-sciences-q4-eps-026-beats-031-estimate

Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

Core News & Articles

-SEC Filing

 lake-street-maintains-buy-on-achieve-life-sciences-lowers-price-target-to-11

Lake Street analyst Thomas Flaten maintains Achieve Life Sciences (NASDAQ:ACHV) with a Buy and lowers the price target from ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION